Functional Medicine in Brea, Orange County, California, Serving Patients Across California, Arizona, Nevada, Oregon & Washington

If you've been diagnosed with mold illness, also known as Chronic Inflammatory Response Syndrome (CIRS), and have already completed the initial steps of treatment including toxin removal with cholestyramine, you may have heard about the next critical phase of recovery: VIP nasal spray.

‍
Vasoactive intestinal peptide (VIP) is a naturally occurring neuropeptide that plays a central role in regulating inflammation, immune balance, blood flow, and neuroprotection throughout the body. In the context of mold illness, VIP nasal spray is used as a late-stage restorative therapy, not a binder, but a powerful immunomodulator that helps recalibrate the immune system after biotoxin exposure has been addressed.

‍
At Mindspark Health, VIP nasal spray therapy for mold illness is available, making expert CIRS care accessible to patients across California, Arizona, Nevada, Oregon, and Washington.

What Is VIP (Vasoactive Intestinal Peptide)?

In mold illness, VIP levels are often found to be deficient, a finding that has also been documented in patients with pulmonary arterial hypertension, where VIP deficiency in serum and lung tissue was accompanied by upregulation of VIP receptors, suggesting the body is "hungry" for this peptide.

How Does VIP Work in Mold Illness?

VIP is not a toxin binder like cholestyramine. Instead, it works downstream in the CIRS treatment protocol, after biotoxins have been removed and inflammatory markers have begun to normalize. VIP addresses the persistent immune dysregulation that remains even after the toxic burden has been cleared.

Why Nasal Spray? The Intranasal Advantage

VIP has an extremely short plasma half-life when administered intravenously, limiting its systemic use. The intranasal route offers several key advantages:

• Direct brain delivery, VIP reaches the central nervous system via the olfactory mucosa, bypassing the blood-brain barrier
• Avoids rapid systemic degradation, intranasal delivery reduces exposure to plasma peptidases that rapidly break down VIP in the bloodstream
• Targeted mucosal delivery, the nasal mucosa is rich in VIP receptors (VPAC1 and VPAC2), making it an ideal site for local and systemic immune modulation
• Minimal systemic side effects, intranasal delivery at therapeutic doses avoids the hypotension and flushing associated with intravenous VIP administration
• Convenient self-administration, patients can use the nasal spray at home as part of their daily protocol

How to Use VIP Nasal Spray: The Do's

• Use only under the care of a certified Shoemaker provider, experienced and well-versed in CIRS treatment protocols. VIP nasal spray is a compounded medication prescribed as part of a comprehensive CIRS treatment protocol. Dosing is individualized.
• Prime the spray bottle before first use. Pump the spray several times until a fine mist appears before your first dose.
• Administer into each nostril as prescribed. Gently insert the tip into one nostril, aim slightly outward (toward the ear), and spray while inhaling gently. Repeat in the other nostril if directed.
• Use at consistent times each day. Maintaining a regular schedule helps sustain steady VIP levels.
• Keep nasal passages clear. If you have significant nasal congestion, gently blow your nose before administration to ensure adequate mucosal contact.
• Continue only under medical supervision. VIP nasal spray is typically introduced only after earlier steps in the CIRS protocol have been completed, including removal from exposure, cholestyramine binding, and normalization of key inflammatory markers. Starting VIP too early can be counterproductive.
• Monitor your biomarkers. Your provider will track inflammatory markers (MMP-9, TGF-β1, C4a, VEGF, MSH, VIP levels) to assess response and guide treatment duration.

What NOT to Do: Critical Precautions

• Do NOT start VIP before completing prior treatment steps. VIP is a late-stage therapy in the CIRS protocol. Using it before biotoxin removal and initial immune stabilization may not produce the desired results and could mask ongoing exposure.
• Do NOT use VIP if you are still living or working in a water-damaged building. Ongoing mold exposure will continue to drive inflammation regardless of VIP therapy. Environmental remediation must come first.
• Do NOT use if you have active infections or untreated MARCoNS. Multiple Antibiotic Resistant Coagulase Negative Staphylococci (MARCoNS), a deep nasal biofilm infection common in CIRS patients, should be treated before starting intranasal VIP, as the biofilm can interfere with VIP absorption and efficacy.

• Use caution if you take blood pressure medications. VIP is a potent vasodilator. While intranasal delivery at therapeutic doses typically does not cause significant systemic blood pressure changes, intravenous VIP has been shown to decrease mean arterial pressure by 10–15% and total peripheral resistance by up to 45%. Patients on antihypertensive medications should be monitored for additive hypotensive effects, especially during initial dosing.
• Use caution if you have a history of low blood pressure or orthostatic hypotension. Report any dizziness, lightheadedness, or flushing to your provider.
• Do NOT share your nasal spray device. Each device is for individual patient use only to prevent contamination and cross-infection.
• Do NOT exceed the prescribed dose. Higher systemic VIP levels can cause flushing, palpitations, abdominal discomfort, and diarrhea.

Potential Side Effects

VIP nasal spray is generally well-tolerated at prescribed intranasal doses. However, potential
side effects may include:

• Mild nasal irritation, typically transient and self-resolving within a week
• Flushing or warm sensations, more common with higher doses or systemic absorption
• Heart palpitations, reported with intravenous VIP; uncommon with intranasal use
• Watery nasal discharge, VIP stimulates serous cell secretion in nasal mucosa, which may cause temporary rhinorrhea
• Abdominal discomfort or diarrhea, rare at intranasal doses; more associated with systemic VIP exposure

If any side effects are persistent or bothersome, contact your provider for dose adjustment.

Storage

Proper storage is essential to maintain VIP nasal spray potency:

• Store refrigerated at 36°F to 46°F (2°C to 8°C). VIP is a peptide and is sensitive to heat degradation. Refrigeration is required to maintain stability.
• Do NOT freeze. Freezing can damage the peptide structure and compromise efficacy.
• Protect from light. Store in the original container or a light-protected bag.
• Keep the cap on when not in use. This prevents contamination and protects the spray mechanism.
• Note the expiration date. Compounded VIP nasal spray typically has a limited beyond-use date (often 30–90 days from compounding). Use within the timeframe specified by your compounding pharmacy.
• Do NOT use if the solution appears cloudy, discolored, or contains particles. A clear solution indicates proper integrity.
• When traveling, transport in an insulated cooler bag with ice packs. Do not leave in a hot car or exposed to direct sunlight.

Who Should Consider VIP Nasal Spray?

VIP nasal spray may be appropriate for individuals who:

• Have been diagnosed with CIRS/mold illness and have completed initial treatment steps (environmental remediation, cholestyramine binding, MARCoNS treatment)
• Have persistent symptoms despite biotoxin removal, fatigue, brain fog, shortness of breath, chronic pain
• Show ongoing inflammatory biomarker abnormalities (elevated TGF-β1, MMP-9, C4a; low VIP, MSH, VEGF)
• Experience chronic respiratory symptoms, sinus issues, or shortness of breath related to mold exposure
• Have documented low VIP levels on lab testing
• Are under the care of a provider experienced in CIRS treatment protocols

How Mindspark Health Approaches VIP Therapy Through Telehealth

At Mindspark Health, VIP nasal spray is prescribed as part of our comprehensive, step-wise CIRS treatment protocol, never as a standalone therapy. Here's how telehealth makes this accessible:

‍
Step 1: Telehealth Consultation‍

● Comprehensive intake covering symptom history, exposure history, prior CIRS treatment, and current medications. Call or text (714) 695-5837 to book.

‍
Step 2: Diagnostic Workup‍

● Lab orders for CIRS biomarkers (MMP-9, TGF-β1, C4a, VEGF, MSH, VIP, ADH/osmolality, leptin), nasal culture for MARCoNS, and VCS screening, all completable at local labs or from home.

‍
Step 3: Step-Wise Treatment Protocol

‍● Treatment follows a structured sequence when addressing remediation, binding, MARCoNS, and VIP:

• Environmental remediation, with confirmed removal from water-damaged building exposure
• Biotoxin binding with cholestyramine to interrupt enterohepatic recirculation of mycotoxins
• MARCoNS treatment if nasal biofilm is present
• Dietary adjustment and metabolic support as clinically indicated
• Hormone optimization and restoration of physiologic balance when needed
• Normalization of ADH and osmolality, along with assessment of innate immune markers
• Anti-inflammatory and regenerative support with peptides such as KPV, BPC-157, TB-500, Thymosin Alpha 1, and GHK-Cu as clinically appropriate
• VIP nasal spray, introduced only after prior steps are completed and biomarkers are trending toward normalization

Step 4: Compounded VIP Prescription

● VIP nasal spray is prescribed from a reputable compounding pharmacy and shipped directly to your home.

Step 5: Ongoing Monitoring‍

● Regular telehealth follow-ups to track biomarker response, adjust VIP dosing, and advance through the recovery protocol. Complementary therapies may include:

• Selank for cognitive support and stress reduction
• DSIP for sleep optimization
• Epithalon for cellular longevity support
• MOTS-c for metabolic optimization

Additional complementary therapies may also include peptides such as

• TB-500
• Thymosin Alpha 1
• GHK-Cu
• Along with herbal compounds, antifungals when indicated, vagal tone exercises, plasmalogen support, gut modulation strategies, and hormone replacement therapy as appropriate

Where can I get treated for mold illness near me?

Mindspark Health in Brea, Orange County, California offers telehealth mold illness evaluation and treatment. We serve patients throughout Orange County (Brea, Fullerton, Anaheim, Irvine, Newport Beach), Los Angeles, the Inland Empire, San Diego, and across California, Arizona, Nevada, Oregon, and Washington.

‍
If you've been struggling with the lingering effects of mold exposure, fatigue, brain fog, respiratory issues, chronic pain, and you've already started treatment but aren't fully recovered, VIP nasal spray may be the missing piece.

And with Mindspark Health's telehealth platform, expert CIRS care is just a phone call away. Call or text Mindspark Health at (714) 695-5837 to schedule your telehealth consultation today, or visit our website to learn more about how to become a patient.

‍

References

1. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Current Pharmaceutical Design. 2007;13(11):1113-1139. doi:10.2174/138161207780618966

‍
2. Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. Journal of Molecular Medicine. 2002;80(1):16-24. doi:10.1007/s00109-001-0291-5

‍
3. Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiologica. 2015;213(2):442-452. doi:10.1111/apha.12427

‍
4. Iwasaki M, Akiba Y, Kaunitz JD. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research. 2019;8:F1000 Faculty Rev-1629.
doi:10.12688/f1000research.18039.1

‍
5. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. Journal of Biological Chemistry. 2001;276(1):369-380. doi:10.1074/jbc.M006923200

‍
6. Goetzl EJ, Pankhaniya RR, Gaufo GO, et al. Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses. Annals of the New York Academy of Sciences. 1998;840:540-550. doi:10.1111/j.1749-6632.1998.tb09593.x

‍
7. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation. 2003;111(9):1339-1346. doi:10.1172/JCI17500

‍
8. Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochemical and Biophysical Research Communications.
2003;302(2):275-283. doi:10.1016/s0006-291x(03)00149-9

‍
9. Leceta J, Gomariz RP, Martinez C, et al. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Annals of the New York Academy of Sciences. 2000;921:92-102. doi:10.1111/j.1749-6632.2000.tb06954.x

‍
10.Sun W, Tadmori I, Yang L, Delgado M, Ganea D. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. Journal of Neuroimmunology. 2000;107(1):88-99. doi:10.1016/s0165-5728(00)00245-9

‍
11. Duan JX, Guan XX, Yang HH, et al. Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition. International Immunopharmacology. 2021;101(Pt B):108211.
doi:10.1016/j.intimp.2021.108211

‍
12.Grimm MC, Newman R, Hassim Z, et al. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. Journal of Immunology. 2003;171(10):4990-4994.
doi:10.4049/jimmunol.171.10.4990

‍
13.Delgado M, Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. Journal of Immunology. 2001;167(2):966-975. doi:10.4049/jimmunol.167.2.966

‍
14.Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal. 2008;32(5):1289-1294. doi:10.1183/09031936.00050008

‍
15.Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. European Respiratory Journal. 2008;31(1):135-139. doi:10.1183/09031936.00105807

‍
16.Cui X, Cao DY, Wang ZM, Zheng AP. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration. Die Pharmazie. 2013;68(1):69-74.

‍
17.Dufes C, Olivier JC, Gaillard F, et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. International Journal of Pharmaceutics. 2003;255(1-2):87-97. doi:10.1016/s0378-5173(03)00039-5

‍
18.Baraniuk JN, Lundgren JD, Okayama M, et al. Vasoactive intestinal peptide in human nasal mucosa. Journal of Clinical Investigation. 1990;86(3):825-831. doi:10.1172/JCI114780

‍
19.Frase LL, Gaffney FA, Lane LD, et al. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. American Journal of Cardiology. 1987;60(16):1356-1361. doi:10.1016/0002-9149(87)90619-9

‍
20.Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovascular Research. 2001;49(1):27-37. doi:10.1016/s0008-6363(00)00229-7

‍
21.Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Network Open. 2021;4(8):e2118543. doi:10.1001/jamanetworkopen.2021.18543